First Adolescent Migraine Prophylactic Approved
The safety and effectiveness in preventing migraine headaches in adolescents (ages 12–17) was established in a clinical trial that enrolled 103 patients. Treatment with Topamax resulted in a decrease in migraine frequency of about 72% compared to 44% in participants that were treated with placebo.
Topamax is already approved as initial monotherapy and adjunct in partial-onset or primary generalized tonic-clonic seizures; as adjunct in Lennox-Gastaut syndrome; and for migraine prophylaxis in adults.
For more information call (800) 526-7736 or visit Topamax.com.